DrugDashboards

Levothyroxine Sodium

Levothyroxine Sodium · LEVOTHYROXINE SODIUM .05 mg/1 · Tablet · Oral · Major Pharmaceuticals

NDC 00904-6950-61 · 100 BLISTER PACK in 1 CARTON / 1 TABLET in 1 BLISTER PACK · ANDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble. The generic price is down 22% over the past year, to $0.0406 per unit. The brand (levothyroxine sodium) runs $1.35 per unit 24× more. 12 Class II recalls hit this product in the past year (Major Pharmaceuticals). Put together: this looks like a healthy supply — the boring kind, which is exactly what you want. Historically, drugs in this position went on to a new shortage within 90 days about 0.5% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.0406per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$0.0923per dosage unitgross, before rebates — matched by drug name · 2024

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.1$0.2$0.3Apr 2020Sep 2026$0.0406
78 price points · per EASource: CMS NADAC

Estimated fill cost

#30 count
$1.22
#90 count
$3.66

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$387
424 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

23Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • Class I/II recall in past 12 months+15
  • price down 22% year over year+8

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.5%chance of a new FDA shortage posting for levothyroxine sodium (oral solid) in the next 90 days

16 Class I/II recall(s) in 12 months · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA209713
TE code
AB1,AB2,AB3
Approval date
Jan 18, 2019
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · OngoingJul 13, 2026
    Major PharmaceuticalsSubpotent Drug
  • Class II · OngoingJul 13, 2026
    Major PharmaceuticalsSubpotent Drug
  • Class II · OngoingJul 13, 2026
    Major PharmaceuticalsSubpotent Drug
  • Class II · OngoingJul 13, 2026
    Major PharmaceuticalsSubpotent Drug
  • Class II · OngoingJul 13, 2026
    Major PharmaceuticalsSubpotent Drug
  • Class II · OngoingJul 13, 2026
    Major PharmaceuticalsSubpotent Drug
  • Class II · OngoingJul 13, 2026
    Major PharmaceuticalsSubpotent Drug
  • Class II · OngoingJul 13, 2026
    Major PharmaceuticalsSubpotent Drug
  • Class II · OngoingJul 13, 2026
    Major PharmaceuticalsSubpotent Drug
  • Class II · OngoingJul 13, 2026
    Major PharmaceuticalsSubpotent Drug
  • Class II · OngoingJul 13, 2026
    Major PharmaceuticalsSubpotent Drug
  • Class II · OngoingJul 13, 2026
    Major PharmaceuticalsSubpotent Drug

Manufacturers of Levothyroxine Sodium (Tablet)

LabelerStrengthFirst seenLast seen
A-S Medication SolutionsLEVOTHYROXINE SODIUM .088 mg/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsLEVOTHYROXINE SODIUM 150 ug/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsLEVOTHYROXINE SODIUM .1 mg/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsLEVOTHYROXINE SODIUM .025 mg/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsLEVOTHYROXINE SODIUM .137 mg/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsLEVOTHYROXINE SODIUM 25 ug/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsLEVOTHYROXINE SODIUM 88 ug/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsLEVOTHYROXINE SODIUM .125 mg/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsLEVOTHYROXINE SODIUM .075 mg/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsLEVOTHYROXINE SODIUM 75 ug/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsLEVOTHYROXINE SODIUM 112 ug/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsLEVOTHYROXINE SODIUM .112 mg/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsLEVOTHYROXINE SODIUM 125 ug/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsLEVOTHYROXINE SODIUM .15 mg/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsLEVOTHYROXINE SODIUM 100 ug/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsLEVOTHYROXINE SODIUM 50 ug/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsLEVOTHYROXINE SODIUM 200 ug/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackLEVOTHYROXINE SODIUM 100 ug/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackLEVOTHYROXINE SODIUM 125 ug/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackLEVOTHYROXINE SODIUM 150 ug/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackLEVOTHYROXINE SODIUM 112 ug/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackLEVOTHYROXINE SODIUM 75 ug/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackLEVOTHYROXINE SODIUM 200 ug/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackLEVOTHYROXINE SODIUM 50 ug/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackLEVOTHYROXINE SODIUM 88 ug/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackLEVOTHYROXINE SODIUM 25 ug/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackLEVOTHYROXINE SODIUM 300 ug/1Jul 15, 2026Sep 3, 2026
Northwind Health Company, LLCLEVOTHYROXINE SODIUM 88 ug/1Jul 15, 2026Sep 3, 2026
Northwind Health Company, LLCLEVOTHYROXINE SODIUM 50 ug/1Jul 15, 2026Sep 3, 2026
Northwind Health Company, LLCLEVOTHYROXINE SODIUM 112 ug/1Jul 15, 2026Sep 3, 2026
Northwind Health Company, LLCLEVOTHYROXINE SODIUM 175 ug/1Jul 15, 2026Sep 3, 2026
NuCare Pharmaceuticals, Inc.LEVOTHYROXINE SODIUM .075 mg/1Aug 27, 2026Sep 3, 2026
NuCare Pharmaceuticals,Inc.LEVOTHYROXINE SODIUM 50 ug/1Jul 15, 2026Sep 3, 2026
Preferred Pharmaceuticals Inc.LEVOTHYROXINE SODIUM 88 ug/1Jul 15, 2026Sep 3, 2026
Preferred Pharmaceuticals Inc.LEVOTHYROXINE SODIUM 100 ug/1Jul 15, 2026Sep 3, 2026
Preferred Pharmaceuticals Inc.LEVOTHYROXINE SODIUM 50 ug/1Jul 15, 2026Sep 3, 2026
Preferred Pharmaceuticals Inc.LEVOTHYROXINE SODIUM 25 ug/1Jul 15, 2026Sep 3, 2026
Preferred Pharmaceuticals Inc.LEVOTHYROXINE SODIUM 175 ug/1Jul 15, 2026Sep 3, 2026
Proficient Rx LPLEVOTHYROXINE SODIUM .112 mg/1Jul 15, 2026Sep 3, 2026
Proficient Rx LPLEVOTHYROXINE SODIUM 100 ug/1Jul 15, 2026Sep 3, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Levothyroxine Sodium — NDC 00904-6950-61," retrieved September 3, 2026, https://drugdashboards.com/drug/00904695061.

Free to cite with attribution — see how the data is put together.